Who
Jeff L. Vacirca
Director
Company insider
Files Form 4 as: Director, Caris Life Sciences; Director, Assertio Holdings; Director, Spectrum Pharmaceuticals; Director, Odonate Therapeutics.
In numbers
- Trades disclosed
- 44
- Buys
- 6
- Sells
- 0
- Bought
- $1.6M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 12 Dec 2017
- Last trade
- 14 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 14 Aug 2026 | CAI Caris Life SciencesDiagnostics & Labs | SEC FORM 4 Code A | —13,192 at $0.00 | filing |
| 14 Aug 2026filed 14 Aug 2026 | CAI Caris Life SciencesDiagnostics & Labs | SEC FORM 4 Code A | —13,192 at $0.00 | filing |
| 11 May 2026filed 12 May 2026 | CAI Caris Life SciencesDiagnostics & Labs | SEC FORM 4 Bought | $501K31,050 at $16.15 | filing |
| 11 May 2026filed 12 May 2026 | CAI Caris Life SciencesDiagnostics & Labs | SEC FORM 4 Bought | $501K31,050 at $16.15 | filing |
| 26 Feb 2026filed 27 Feb 2026 | CAI Caris Life SciencesDiagnostics & Labs | SEC FORM 4 Code A | $50K2,492 at $20.06 | filing |
| 26 Feb 2026filed 27 Feb 2026 | CAI Caris Life SciencesDiagnostics & Labs | SEC FORM 4 Code A | $50K2,492 at $20.06 | filing |
| 11 Jun 2024filed 12 Jun 2024 | Assertio Holdings | SEC FORM 4 Bought | $11K10,000 at $1.11 | filing |
| 23 May 2024filed 28 May 2024 | Assertio Holdingsoption or derivative | SEC FORM 4 Code A | —81,225 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | Assertio Holdings | SEC FORM 4 Code A | —53,750 at $0.00 | filing |
| 31 Jul 2023filed 2 Aug 2023 | Assertio Holdingsoption or derivative | SEC FORM 4 Code A | —5,005 at $0.00 | filing |
| 31 Jul 2023filed 2 Aug 2023 | Assertio Holdings | SEC FORM 4 Code A | —52,642 | filing |
| 31 Jul 2023filed 2 Aug 2023 | Assertio Holdings | SEC FORM 4 Code A | —34,767 at $0.00 | filing |
| 31 Jul 2023filed 1 Aug 2023 | Spectrum Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —75,000 | filing |
| 31 Jul 2023filed 1 Aug 2023 | Spectrum Pharmaceuticals | SEC FORM 4 Code D | —295,244 | filing |
| 30 Nov 2022filed 2 Dec 2022 | Spectrum Pharmaceuticals | SEC FORM 4 Bought | $23K50,000 at $0.45 | filing |
| 27 Oct 2022filed 27 Oct 2022 | Spectrum Pharmaceuticals | SEC FORM 4 Code A | $22K50,000 at $0.43 | filing |
| 31 Aug 2022filed 2 Sep 2022 | Spectrum Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 31 Aug 2022filed 2 Sep 2022 | Spectrum Pharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 14 Feb 2022filed 14 Feb 2022 | Spectrum Pharmaceuticals | SEC FORM 4 Code A | $6,80010,000 at $0.68 | filing |
| 17 Jun 2021filed 22 Jun 2021 | Spectrum Pharmaceuticals | SEC FORM 4 Code A | —14,277 at $0.00 | filing |
News
Caris Life Sciences (NASDAQ:CAI) Stock Price Target Raised at JPMorgan Chase & Co.CAI · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Jeff L. Vacirca; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.